Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes

A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with type 2 diabetes and overweight or obesity.